Navigation Links
UofL awarded $9.56 million to form first-ever multicenter cardiovascular research network

LOUISVILLE, Ky. The National Heart, Lung and Blood Institute has awarded $9.56 million over five years to a University of Louisville Health Sciences Center research scientist to form a multi-center network examining cardioprotective therapies at the preclinical level.

Dr. Roberto Bolli, director of the Institute of Molecular Cardiology and chief of the Division of Cardiovascular Medicine at UofL, is principal investigator of the "CAESAR Project" a consortium for preclinical assessment of cardioprotective therapies that will involve laboratories at UofL, Johns Hopkins University in Baltimore, Emory University in Atlanta and Virginia Commonwealth University in Richmond.

The four-center project marks the first time the National Institutes of Health has funded a network of laboratories to test cardioprotective therapies at the preclinical level using the same scientific rigor as applied in clinical trials.

The multi-center network being established will be available to all investigators in the nation so that data can be shared with the goal of ultimately translating this type of basic research into clinically applicable therapies for patients with acute myocardial infarction, Bolli said.

Specifically, the researchers will perform blinded, randomized animal studies to examine how to lessen the damage done to heart muscle in a heart attack. An estimated 1.3 million Americans have a myocardial infarction a heart attack each year. The prognosis of these patients is dependent upon the size of the infarct the larger the infarct, the greater the likelihood of subsequent heart failure and death. Also, the damage done to the heart is irreversible; once heart muscle is lost to an infarct, it is dead tissue that cannot be reclaimed.

For almost 40 years, the NIH/NHLBI has invested considerable resources in preclinical studies aimed at developing infarct-sparing therapies. Throughout this time, hundreds of therapies have been developed that have been claimed to limit infarct size in preclinical models. However, Bolli said, none have advanced to the clinical stage.

"This enormous investment at least several hundred million dollars over the past 40 years has not produced any notable clinical application. Results have generally not been replicated in from one lab to another, and no cardioprotective therapy is currently available for clinical use," Bolli said. "Approximately eight years ago, I began talking with NIH representatives about the need to change how we are conducting cardioprotective preclinical studies. Those conversations have led to this grant."

One key change in how these studies are conducted is the addition of a statistician in developing the research study design. Another is ensuring reproducibility; each study will be performed in two centers using identical protocols, with each center unaware of the other's results.

The goal of the project is to identify therapies that are proven to work through rigorous study in preclinical models and ultimately advance them to clinical trial stage.

"CAESAR will be a major paradigm shift in cardioprotection. By screening promising therapies and identifying those that are truly effective in relevant experimental models and thus, are most likely to be ultimately effective in patients CAESAR will focus clinical trials on those therapies and will dramatically advance our ability to rationally translate basic findings into clinical trials," Bolli said.

"Dr. Bolli's career continues to be distinguished by his efforts to develop innovative solutions for fighting heart disease, the leading cause of death in the United States," said Dr. James R. Ramsey, president of the University of Louisville. "By conceiving, creating and leading this network Dr. Bolli demonstrates daily how the people at the University of Louisville strive to find ways to improve the lives of people in Kentucky and beyond."

Joining Bolli in the research at UofL are Dr. Xian-Liang Tang, associate professor of medicine, Dr. Yiru Guo, associate professor of medicine, Dr. Qianhong Li, assistant professor of medicine, and Dr. Steven Jones, associate professor of medicine, all with the Division of Cardiovascular Medicine in the Department of Medicine; and Dr. Maiying Kong, associate professor of bioinformatics and biostatistics in the School of Public Health and Information Sciences.

Leading the efforts at the other university centers are Dr. Charles Steenbergen at Johns Hopkins; Dr. David Lefer and Dr. Jakob Vinten-Johansen at Emory; and Dr. Rakesh Kukreja at Virginia Commonwealth.


Contact: Jill Scoggins
University of Louisville

Related medicine news :

1. San Diego Unified School District Awarded Silent Hero Grant From got breakfast?(R) Foundation
2. $250,000 grant awarded for groundbreaking ligament and tendon repair research
3. $250,000 Grant Awarded for Groundbreaking Ligament and Tendon Repair Research
4. $300,000 CIHR grant awarded to Medicago, the Research Institute of the MUHC and McGill University
5. Hard to Treat Diseases (HTDS) Awarded Two Antibiotics Certificates For Chile
6. MEDNET and Hielix Awarded the State of North Dakota Contract for Statewide Health Information Exchange (HIE) Strategic and Operational Plans
7. Centenes Arizona Behavioral Health Unit Awarded Expanded Contract
8. Bloomberg School of Public Health awarded $15 million for laboratory renovation and modernization
9. New York College of Osteopathic Medicine (NYCOM) at NYIT Awarded $1 Million Federal Grant
10. Kineta Awarded NIH Grant to Complete Preclinical Studies on Type 1 Diabetes / Multiple Sclerosis Drug Candidate
11. Canadian research team awarded international grant for work on Indigenous peoples health
Post Your Comments:
(Date:10/13/2017)... ... 2017 , ... As health professionals work to improve their approach to healthcare, ... doing more than filling out a survey; in many cases health professionals and patients ... health care and research on the importance of active engagement with patients and members ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Pa. , Oct. 12, 2017 ... leader in innovative solutions for injectable drug administration, today ... before the market opens on Thursday, October 26, 2017, ... the results and business expectations at 9:00 a.m. Eastern ... (U.S.) or 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance in ... medical-grade battery-powered display stand specifically designed for endoscopy environments. An innovative ... into a clinical solution to support the improvement of patient outcomes, ... Design ... Solution ...
(Date:10/4/2017)... 4, 2017  According to the Centers for Disease Control and Prevention ... . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the month. ... health insurance regulations. ... to get a flu shot is by the end of October, according ...
Breaking Medicine Technology: